Ambion, Inc.'s Former CEO And Founder Launches Asuragen, Inc.
AUSTIN, Texas--(BUSINESS WIRE)--March 14, 2006--The completion of the $273M sale of Ambion's Research Products Division to Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, resulted in the simultaneous spin-off of Asuragen, Inc. Asuragen is a newly formed molecular diagnostic company led by Matt Winkler, founder and former CEO of Ambion, Inc.